Esperion (0ET) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0ET Analyst Ratings

Moderate Buy

4 Buy

1 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Esperion

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0ET Stock 12 Month Forecast

Average Price Target

CHF5.16

Based on 6 Wall Street analysts offering 12 month price targets for Esperion in the last 3 months. The average price target is CHF5.16 with a high forecast of CHF13.09 and a low forecast of CHF1.51. The average price target represents a ― change from the last price of ―.

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

Highest Price TargetCHF13.09

Average Price TargetCHF5.16

Lowest Price TargetCHF1.51

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph PantginisH.C. Wainwright

H.C. Wainwright

CHF13.44

Buy

―

Reiterated

05/08/25

Esperion's Strategic Expansion and Promising Financial Outlook Earns Buy Rating

Serge BelangerNeedham

Needham

CHF4.2→CHF3.36

Buy

―

Reiterated

05/06/25

Esperion's Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances

Jason ZemanskyBank of America Securities

Bank of America Securities

CHF1.55

Sell

―

Reiterated

04/23/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (NASDAQ: CTKB), Esperion (NASDAQ: ESPR) and PROCEPT BioRobotics (NASDAQ: PRCT)

Paul ChoiGoldman Sachs

Goldman Sachs

CHF3.36→CHF2.52

Hold

―

Reiterated

04/16/25

Esperion Therapeutics (ESPR) PT Lowered to $3 at Goldman SachsGoldman Sachs analyst Paul Choi lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $3.00 (from $4.00) while maintaining a Neutral rating.

Jason ButlerCitizens JMP

Citizens JMP

CHF3.36

Buy

―

Reiterated

03/24/25

Esperion's Strategic Growth: Phase 3 Expansion and Patent Protection Boost Valuation

Thomas ShraderBTIG

BTIG

CHF7.56

Buy

―

Reiterated

03/04/25

Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

CHF6.72

Buy

―

Initiated

12/17/24

Cantor Fitzgerald starts Esperion Therapeutics (ESPR) at OverweightCantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Overweight rating and a price target of $8.00.

Dennis DingJefferies

Jefferies

CHF4.2

Buy

―

Reiterated

12/10/24

Esperion's Strategic Pipeline Advancements and Market Recovery Drive Buy Rating Amidst Cholesterol Competition

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph PantginisH.C. Wainwright

H.C. Wainwright

CHF13.44

Buy

―

Reiterated

05/08/25

Esperion's Strategic Expansion and Promising Financial Outlook Earns Buy Rating

Serge BelangerNeedham

Needham

CHF4.2→CHF3.36

Buy

―

Reiterated

05/06/25

Esperion's Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances

Jason ZemanskyBank of America Securities

Bank of America Securities

CHF1.55

Sell

―

Reiterated

04/23/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (NASDAQ: CTKB), Esperion (NASDAQ: ESPR) and PROCEPT BioRobotics (NASDAQ: PRCT)

Paul ChoiGoldman Sachs

Goldman Sachs

CHF3.36→CHF2.52

Hold

―

Reiterated

04/16/25

Jason ButlerCitizens JMP

Citizens JMP

CHF3.36

Buy

―

Reiterated

03/24/25

Esperion's Strategic Growth: Phase 3 Expansion and Patent Protection Boost Valuation

Thomas ShraderBTIG

BTIG

CHF7.56

Buy

―

Reiterated

03/04/25

Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

CHF6.72

Buy

―

Initiated

12/17/24

Dennis DingJefferies

Jefferies

CHF4.2

Buy

―

Reiterated

12/10/24

Esperion's Strategic Pipeline Advancements and Market Recovery Drive Buy Rating Amidst Cholesterol Competition

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Esperion

1 Month

xxx

Success Rate

7/16 ratings generated profit

Average Return

+6.51%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of +6.51% per trade.

3 Months

xxx

Success Rate

5/16 ratings generated profit

Average Return

-3.24%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 31.25% of your transactions generating a profit, with an average return of -3.24% per trade.

1 Year

Thomas ShraderBTIG

Success Rate

8/24 ratings generated profit

Average Return

+18.15%

reiterated a buy rating 3 months ago

Copying Thomas Shrader's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +18.15% per trade.

2 Years

xxx

Success Rate

4/24 ratings generated profit

Average Return

-29.46%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -29.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0ET Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0ET has received 12 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. 0ET average Analyst price target in the past 3 months is 5.16.

Each month's total comprises the sum of three months' worth of ratings.

0ET Financial Forecast

0ET Earnings Forecast

Next quarter’s earnings estimate for 0ET is -CHF0.12 with a range of -CHF0.16 to -CHF0.08. The previous quarter’s EPS was -CHF0.18. 0ET beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.06% of the time in the same period. In the last calendar year 0ET has Outperformed its overall industry.

0ET Sales Forecast

Next quarter’s sales forecast for 0ET is CHF52.18M with a range of CHF44.55M to CHF59.90M. The previous quarter’s sales results were ―. 0ET beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year 0ET has Outperformed its overall industry.

0ET Stock Forecast FAQ

What is CH:0ET’s average 12-month price target, according to analysts?

Based on analyst ratings, Esperion’s 12-month average price target is 5.16.

What is CH:0ET’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:0ET, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Esperion a Buy, Sell or Hold?

Esperion has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 1 hold ratings and 1 sell ratings.

What is Esperion’s share price target?

The average share price target for Esperion is 5.16. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF13.09 ,and the lowest forecast is CHF1.51. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Esperion?

Esperion’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Esperion?

To buy shares of CH:0ET, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Esperion (0ET) Stock Forecast & Price Target

0ET Analyst Ratings

0ET Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Esperion

0ET Analyst Recommendation Trends

0ET Financial Forecast

0ET Earnings Forecast

0ET Sales Forecast

0ET Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts